CEO Council for Growth | CGTCH

Life Sciences PA Shares Industry Impact Report

A new study commissioned by Life Sciences Pennsylvania examines how the region continues to lead the way in fostering growth and success in the life sciences industry.

Learn more

Discovery Starts with Imvax’s Raechel Manrodt

Raechel Manrodt, Manufacturing Lead (Director) at Imvax, discusses her role in leveraging Imvax's unique immunotherapy platform to develop a pipeline of personalized treatments targeting cancers.

Learn more

It’s a High Five for Philadelphia in JLL Report

JLL’s 2022 Life Sciences Research Outlook & Cluster Rankings places Greater Philadelphia in the top five as a cell and gene therapy sector leader.

Learn more

MORE TO DISCOVER

Share the Greater Philadelphia Region’s success stories with the Chamber's Cell & Gene Therapy and Connected Health Initiative toolkit.

View the Toolkit

ChristianaCare spins out first commercial gene-editing company named CorriXR Therapeutics to advance CRISPR therapies.

Cabaletta Bio announces CABA-201, a newly designed CD19 targeting CAR-T Cell Therapy with an exclusive in-license from Nanjing IASO Biotherapeutics.

Carisma Therapeutics reaches merger agreement with Sesen Bio, to be headquartered in Philadelphia.

Penn Medicine study discovers new gene therapy that rapidly improves night vision in adults with congenital blindness.

Why Philly ranks #2 among best cell and gene therapy hubs in the U.S.

Stay Connected

Join The Mailing List

Thank you to our investors in the Cell & Gene Therapy and Connected Health Initiative:
Amerisource Bergen, Aramark, Children's Hospital of Philadelphia, ChristianaCare, Comcast, Drexel University, Independence Blue Cross, Jefferson Health, Macquarie Group, Penn Medicine, and University of Pennsylvania.

CEO COUNCIL FOR GROWTH
200 S. Broad Street, Suite 700 / Philadelphia, PA 19102 / CEOCouncilForGrowth.com

Click here to be removed from this list
This email was sent to the following email address: ??UserEmail??